FDA Pipeline: Updates on Treatments in NSCLC and Lymphomas, Plus New Dosimetry Software

January 30, 2019 – The U.S. Food and Drug Administration (FDA) recently granted the following application, designations, and clearance: sBLA for Atezolizumab Plus Chemotherapy for First-Line Treatment of Metastatic, Nonsquamous NSCLC. On January 17, the FDA accepted a supplemental biologics license application (sBLA) for atezolizumab in combination with nanoparticle albumin–bound (nab)-paclitaxel and carboplatin for first-line treatment of patients … (leggi tutto)